Clinical trials: Macular Edema
Macular Edema, Retinal Vein Occlusion
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
- Trial name
- COBALT (NCT01903720)
- Testing
- dexamethasone implant
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Allergan
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants…
- Trial name
- RUBY (NCT02712008)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 51 sites in United States
- Volunteers
- 302 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Retinopathy
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs.
- Trial name
- DIVERSE (NCT02366468)
- Testing
- ranibizumab 0.5 mg
- Where
- 30 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Micropulse for Suppression of Diabetic Macular Edema
Diabetic retinopathy is one of the most common complications of diabetes and diabetic macular edema (DME) is one of the most common causes of vision loss in diabetes.
- Trial name
- PULSE (NCT03519581)
- Testing
- Micropulse Laser Treatment
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Davis
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Cystoid Macular Edema
Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Purpose: Study the effect of nepafenac ophthalmic suspension 0.1% to prevent post-operative cystoid macular edema following uncomplicated cataract surgery Participants: Patients having cataract surgery at UNC who meet eligibility…
- Trial name
- NCT00494494
- Testing
- Standard Care, nepafenac
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of North Carolina, Chapel Hill
Retinal Vein Occlusion, Diabetic Macular Edema
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or…
- Trial name
- Molokini (NCT02245516)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- Blossom (NCT01976338)
- Testing
- Ranibizumab 0.5 mg
- Where
- 33 sites in China, Hong Kong and 4 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema
- Trial name
- NCT00768040
- Testing
- Aliskiren
- Where
- 12 sites in United States, Denmark
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Epiretinal Membrane
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
This study will examine the use of the dexamethasone implant (Ozurdex) in patients with macular edema associated with an epiretinal or preretinal membrane requiring surgical intervention.
- Trial name
- OPERA (NCT01613716)
- Testing
- Ozurdex
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RISE (NCT00473330)
- Testing
- Ranibizumab
- Volunteers
- 377 people
- Sponsor
- Genentech, Inc.
Macular Edema, Diabetic Mellitus
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
The purpose of the study to assess the efficacy of pegaptanib sodium 0.3 mg comparing sham injection and to confirm safety of pegaptanib sodium 0.3 mg in subjects with diabetic macular edema.
- Conditions
- Macular Edema, Diabetic Mellitus, Retinal Disease
- Trial name
- NCT01100307
- Testing
- pegaptanib sodium
- Where
- 43 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Pfizer
Retinal Vein Occlusion
Minocycline to Treat Branch Retinal Vein Occlusion
Background: Branch retinal vein occlusion (BRVO) is a blockage of the small veins that carry blood away from the retina in the back of the eye.
- Trial name
- NCT01468831
- Testing
- Minocycline, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 9 people
- Sponsor
- National Eye Institute (NEI)
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Central Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
- Trial name
- RAVEN (NCT03810313)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 120 sites in United States, Australia and 18 more
- Volunteers
- 493 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular…
- Trial name
- REVEAL (NCT00989989)
- Testing
- Ranibizumab, Laser photocoagulation
- Where
- 35 sites in China, Hong Kong and 4 more
- Volunteers
- 396 people
- Sponsor
- Novartis
Macular Edema, Cystoid, Vision Disorders
Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
This study is undertaken to determine the effect of intravitreal long acting dexamethasone implant, (Ozurdex®) in improving outcome of cataract surgery in patients with diabetic macular edema.
- Conditions
- Macular Edema, Cystoid, Vision Disorders, Diabetic Macular Edema, Cystoid Macular Edema Following Cataract Surgery
- Trial name
- NCT01546402
- Testing
- Dexamethasone Drug delivery system (Ozurdex), Cataract surgery
- Where
- India
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Diabetic Macular Edema, Retina Vein Occlusion
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema…
- Trial name
- NCT04085341
- Testing
- GB-102
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Graybug Vision
Macular Edema Associated With Diabetes Mellitus
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy.
- Trial name
- NCT00605280
- Testing
- Standard of Care, Macugen
- Where
- 73 sites in United States, Australia and 16 more
- Volunteers
- 317 people
- Sponsor
- Pfizer